Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma

Q Zhang, L Xiong, T Wei, Q Liu, L Yan, J Chen, L Dai… - Oncogene, 2023 - nature.com
Emerging evidence has indicated that peroxisome proliferator-activated receptor-gamma
coactivator-1α (PPARGC1A) is involved in hepatocellular carcinoma (HCC). However, its …

CITED2 is a novel direct effector of peroxisome proliferator‐activated receptor γ in suppressing hepatocellular carcinoma cell growth

KF Cheung, J Zhao, Y Hao, X Li, AW Lowe… - Cancer, 2013 - Wiley Online Library
BACKGROUND: Previous reports from these authors found that activation of peroxisome
proliferator‐activated receptor gamma (PPARγ) suppressed hepatocellular carcinoma …

PPARγ coactivator‐1α suppresses metastasis of hepatocellular carcinoma by inhibiting Warburg effect by PPARγ–dependent WNT/β‐catenin/pyruvate …

Q Zuo, J He, S Zhang, H Wang, G Jin, H Jin… - …, 2021 - Wiley Online Library
Background and Aims Peroxisome proliferator‐activated receptor‐gamma (PPARγ)
coactivator‐1α (PGC1α) is a key regulator of mitochondrial biogenesis and respiration …

[HTML][HTML] Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway

N Zhang, ESH Chu, J Zhang, X Li, Q Liang, J Chen… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Peroxisome proliferator-activated receptor alpha (PPARα) ligands have been reported to
suppress cancer growth. However, the role of PPARα in hepatocarcinogenesis remains …

[HTML][HTML] Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4

Y Shu, Y Lu, X Pang, W Zheng, Y Huang, J Li, J Ji… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Peroxisome proliferator-activating receptor γ (PPARγ), a transcription factor, is involved in
many important biological processes, including cell terminal differentiation, survival and …

[PDF][PDF] Hepatic peroxisome proliferator‐activated receptor γ coactivator 1β drives mitochondrial and anabolic signatures that contribute to hepatocellular carcinoma …

E Piccinin, C Peres, E Bellafante, S Ducheix… - …, 2018 - Wiley Online Library
The peroxisome proliferator‐activated receptor γ (PPARγ) coactivator‐1β (PGC‐1 β) is a
master regulator of mitochondrial biogenesis and oxidative metabolism as well as of …

PPARδ reprograms glutamine metabolism in sorafenib-resistant HCC

MJ Kim, YK Choi, SY Park, SY Jang, JY Lee… - Molecular Cancer …, 2017 - AACR
The tyrosine kinase inhibitor sorafenib is the only therapeutic agent approved for the
treatment of advanced hepatocellular carcinoma (HCC), but acquired resistance to sorafenib …

Decreased expression of peroxisome proliferator-activated receptor alpha indicates unfavorable outcomes in hepatocellular carcinoma

Y Xiao, S Cai, L Liu, X Yang, J Yun - Cancer management and …, 2018 - Taylor & Francis
Introduction Hepatocellular carcinoma (HCC) has a close relationship with lipid metabolism.
Peroxisome proliferator-activated receptor α (PPARα) plays a crucial role in the regulation of …

[HTML][HTML] The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma

C Wang, L Dong, X Li, Y Li, B Zhang, H Wu… - Free Radical Biology …, 2021 - Elsevier
Targeting energy metabolism holds the potential to effectively treat a variety of malignant
diseases, and peroxisome proliferator-activated receptor gamma coactivator 1 alpha …

PPARγ signaling in hepatocarcinogenesis: mechanistic insights for cellular reprogramming and therapeutic implications

SM Ishtiaq, MI Arshad, JA Khan - Pharmacology & Therapeutics, 2022 - Elsevier
Liver cancer or hepatocellular carcinoma (HCC) is leading cause of cancer-related
mortalities globally. The therapeutic approaches for chronic liver diseases-associated liver …